Impact of insulin therapy before donation on graft outcomes in pancreas transplantation: An analysis of the OPTN/UNOS database
| Autor: | Enrique Montagud-Marrahi, Fritz Diekmann, Vicens Torregrosa, Mireia Musquera, Enric Esmatjes, David Cucchiari, Josep M. Campistol, Nuria Esforzado, Antonio J. Amor, Alicia Molina-Andujar, María José Ramírez-Bajo, Joaquim Casals, Federic Oppenheimer, J. M. Ferrer, Frederic Cofan, Pedro Ventura-Aguiar, Beatriu Bayés, Ignacio Revuelta |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Surgical complication business.industry Endocrinology Diabetes and Metabolism medicine.medical_treatment Insulin Patient survival General Medicine Pancreas transplantation medicine.disease Gastroenterology Endocrinology medicine.anatomical_structure Internal medicine Donation Diabetes mellitus Internal Medicine medicine Humans Pancreas Transplantation business Pancreas Kidney transplantation |
| Zdroj: | Diabetes Research and Clinical Practice. 182:109120 |
| ISSN: | 0168-8227 |
| DOI: | 10.1016/j.diabres.2021.109120 |
| Popis: | Aims Information on the impact of insulin therapy before pancreas donation on pancreas outcomes is scarce. We aim to explore the influence of insulin therapy before donation on recipient and pancreas graft survival. Methods Registry study including 12,841 pancreas recipients from the OPTN/UNOS registry performed between 2000 and 2017. Inverse probability of treatment weighting (IPTW) was used to account for covariate imbalance between recipients from a donor with and without insulin requirements. Results A total of 7765 (60%) patients received a pancreas from a donor with insulin before donation (IBD). Pancreas graft survival (death-censored) was similar between recipients from IBD and non-IBD donors at 1, 5 and 10 years (89% vs 89%, 78% vs 79 and 69% vs 70%, respectively, P = 0.35). Recipients from IBD donors presented a similar 90-days pancreas graft survival. After IPTW weighting, IBD donors were neither associated with any post-transplant surgical complication (HR 1.11 [95% CI 0.98–1.24], P = 0.06), nor with risk for recipient death (HR 0.94 [95% CI 0.85–1.04], P = 0.26), nor pancreas graft failure (HR 1.06 [95% CI 0.98–1.16], P = 0.15). Conclusions Insulin therapy before donation in accepted pancreas donors was not associated, per se, with an impaired pancreas graft and patient survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect